Not available
Quote | Acceleron Pharma Inc. (NASDAQ:XLRN)
Last: | $178.75 |
---|---|
Change Percent: | -0.52% |
Open: | $179.85 |
Close: | $178.75 |
High: | $179.85 |
Low: | $177.06 |
Volume: | 7,581,781 |
Last Trade Date Time: | 11/19/2021 04:56:52 pm |
News | Acceleron Pharma Inc. (NASDAQ:XLRN)
CyrusOne (CONE) and CoreSite (COR) agreed to be acquired in deals valued at $15 billion and $10 billion, respectively. Data centers have been a significant area of growth over the last couple of decades. Ranked by colocation and data center revenues, CyrusOne and CoreSite are the ...
Avoro Capital Advisors, a significant shareholder of Acceleron Pharma (XLRN +3.3%), has reiterated its opposition to the buyout offer made by Merck (MRK -1.2%). The third biggest shareholder of Acceleron (NASDAQ:XLRN) argues that the transaction “is ill-timed, undervalues the Company, ...
Message Board Posts | Acceleron Pharma Inc. (NASDAQ:XLRN)
Subject | By | Source | When |
---|---|---|---|
znewcar1: XLRN 5% v1.2M c90.78 F53M gap up four days ago with big vol and maintained the S@$78 with | znewcar1 | investorshangout | 02/03/2020 4:04:55 AM |
$XLRN: NEWS........ 60% POPPER Sotatercept | makinezmoney | investorshub | 01/28/2020 12:20:41 PM |
Shares of Acceleron Pharma Inc. ($XLRN) are moving | crudeoil24 | investorshub | 11/08/2019 7:21:43 PM |
Heard we got news today | PennyStock Alert | investorshub | 09/17/2019 3:36:51 PM |
This company has good products but has a | faxedreceipts | investorshub | 07/27/2018 9:29:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Acceleron Pharma Inc. Company Name:
XLRN Stock Symbol:
NASDAQ Market:
Acceleron Pharma Inc. Website:
Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Ready to Hel...
In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. However, the big drugmaker recently revealed that it withdrew a key regulatory filing document related to the transaction. In this Motley Fool Live video ...